Press Release: Novartis R&D day spotlights -2-

CVRR-LDL-C - Cardiovascular risk reduction - LDL-C; CVRR-Lp(a) - Cardiovascular risk reduction - Lp(a); C3G - Complement 3 glomerulopathy; IgAN - IgA nephropathy; HS - Hidradenitis suppurativa; GCA - Giant cell arteritis; CSU - Chronic spontaneous urticaria; CINDU - Chronic inducible urticaria; SMA IT - Spinal muscular atrophy - Intrathecal; MS - Multiple sclerosis; HR+/HER2- BC - Hormone receptor positive/ human epidermal growth factor receptor 2 positive breast cancer; mCRPC - Metastatic castration-resistant prostate cancer; mHSPC - Metastatic hormone-sensitive prostate cancer; NSCLC - Non-small cell lung cancer; PDAC - Pancreatic ductal adenocarcinoma; aHUS - Atypical hemolytic uremic syndrome; PNH - Paroxysmal nocturnal hemoglobinuria; CML - Chronic myelogenous leukemia; HR-MDS - Higher-risk myelodysplastic syndromes; DLBCL - Diffuse large B-cell lymphoma

References

1. Smolen J, Nash P, Tahir H, Schulze-Koops H, Li L, Hojnik M, Gellett A,

Liu-Leage S, Pillai S, Mease P. Ianalumab (VAY736), a Dual Mode of Action

Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for

Treatment of Primary Sjögren's Syndrome: Results of an International

Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients

[abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

https://acrabstracts.org/abstract/ianalumab-vay736-a-dual-mode-of-action-biologic-combining-baff-receptor-inhibition-with-b-cell-depletion-for-treatment-of-primary-sjogrens-syndrome-results-of-an-international-randomized/.

Accessed November 2021.

2. Flinn, I. et al. A First-in-Human Study of YTB323, a Novel, Autologous

CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge

platform, for the Treatment of Patients (Pts) with Relapsed/Refractory

(r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Oral Presentation #740. 2021

American Society of Hematology (ASH) Annual Meeting, Dec 11-14, Atlanta,

GA and Virtual.

3. Sperling, A. et al. Phase I Study of PHE885, a Fully Human BCMA-Directed

CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured

in<2 days Using the T-Charge. Poster #3864. 2021 American Society of

Hematology (ASH) Annual Meeting, Dec 11-14, Atlanta, GA and Virtual.

4. Parkinson's Foundation. Parkinson's Disease Statistics.

https://www.parkinson.org/Understanding-Parkinsons/Statistics. Accessed

November 2021.

5. Parkinson's Foundation. Parkinson's Disease Treatment.

https://www.parkinson.org/Understanding-Parkinsons/Treatment. Accessed

November 2021.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Richard Jarvis Julie Masow

Novartis Strategy & Financial Comms Novartis US External Engagement

+41 79 584 23 26 (mobile) +1 862 579 8456

richard.jarvis@novartis.com Julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Thomas Hungerbuehler +41 61 324 8425 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912

(END) Dow Jones Newswires

December 02, 2021 01:15 ET (06:15 GMT)